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ABSTRACT 
Objective: The objective of the present work was to formulate a gastroretentive dosage form of Valacyclovir, an anti viral drug. 
Methods: Valacyclovir gastroretentive mucoadhesive tablets were prepared using polymers such as Carbopol 974P and hydroxy propyl methyl 
cellulose (HPMC) K4M, in different proportions by wet granulation technique. Compatibility studies were performed by FTIR spectroscopy. The 
prepared granules were evaluated for bulk density, Carr’s index, Hausner’s ratio, friability, drug content uniformity, hardness, thickness and post 
compression parameters. 
Results: Results revealed that all the formulated tablets have acceptable physical properties. Based on the in vitro release profile, the formulation 
B3, containing HPMC (46%), Carbopol (15%) with a drug release of 96.98% was chosen as the optimized batch. The B3 formulation was subjected 
for zero order and first order kinetics, Higuchi matrix and peppa’s model. It was found to be adherent to the Higuchi model, as the r
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 value was 
higher thereby following Fickian diffusion. Results of in vitro gastric retention time study indicated that the tablet remained adhered to the stomach 
mucosa and could be seen at the same position after 24h of administration. 
Conclusion: The present formulation, i.e. a gastroretentive drug delivery system can be used as an alternative to conventional dosage forms of 




Valacyclovir is an antiviral drug, mainly acting by interfering with 
viral replication, reducing the physical severity of an outbreak 
associated lesions, and lowering the chance of transmission to 
others. Studies of vulnerable patient populations have indicated that 
daily use of antiviral such as Valacyclovir can help reduce Herpes 
reactivation rates [1]. 
The oral route is considered to be the most promising route of drug 
delivery. Oral drug delivery has been known for decades as the most 
widely utilized route of administration among all routes [2,3]. 
Conventional drug delivery system achieves as well as maintains the 
drug concentration within the therapeutically effective range 
needed for treatment, only when taken several times a day. This 
result in a significant fluctuation in drug concentration; hence the 
need for a gastroretentive drug delivery system. Technical 
advancements of maintaining the drug in the gastro intestinal tract 
is known as gastroretentive oral controlled released dosage form. By 
this approach, it is possible to prolong gastric residence time, 
thereby targeting site specific drug release in the upper gastro 
intestinal tract for local and systemic effects [4]. It has considerable 
therapeutic advantages such as ease of administration, improved 
patient compliance, prolonged gastric emptying time and flexibility 
in formulation. The ability to maintain the delivery system to a 
particular location for an extended period of time has a great appeal 
for both local disease treatment as well as systemic drug 
bioavailability [2]. To formulate a successful stomach specific or 
gastroretentive drug delivery system, several techniques are 
currently used such as hydrodynamically balanced systems (HBS) / 
floating drug delivery system [5], low density systems, raft systems 
[6], incorporating alginate gels, bioadhesive or mucoadhesive 
systems [7], high density systems, super porous hydrogels [8] and 
magnetic systems. Mucoadhesive dosage forms provide intimate 
contact between the dosage form and the absorbing tissue, which 
may result in high-localized drug concentration and hence, high drug 
flux across the absorbing tissue. Furthermore, intimate contact is 
likely to increase the total permeability of high molecular weight 
drugs such as peptides and proteins. By incorporating a permeation 
enhancer, drug absorption through the mucous membrane can be 
enhanced and thus increase the bioavailability of the drug [9]. Using 
a combination of HPMC (K4M), Carbopol 974P, Microcrystalline 
cellulose and PVP, the development of a gastroretentive drug 
delivery system is hereby postulated [10]. Since Valacyclovir has 
less absorption in the basic pH the gastroretentive dosage form will 
cause Valacyclovir to remain in the acidic pH of the stomach for a 
longer duration with the added benefit of improved absorption.  
Therefore an attempt has made to increase the oral bioavailability of 
Valacyclovir by retaining the dosage form in the stomach for a 
longer period of time.  
MATERIALS AND METHODS 
Materials 
Valacyclovir was obtained as a gift from Hetero laboratories, 
Hyderabad. Hydroxy propyl methyl cellulose (HPMC) K4M, 
Microcrystalline cellulose (MCC), Carbopol 974P, Polyvinyl 
pyrolidine (PVP), Talc, Magnesium Stearate, Lactose and Potassium 
chloride are purchased from SD Fine chemicals, Mumbai. 
Acetonitrile HPLC grade and Hydrochloric acid (HCl) was procured 
from Merck, Mumbai. Triple distilled water was obtained from Milli 
Q RO system. 
Methods 
Preparation of calibration curve 
A standard drug solution of Valacyclovir was prepared by dissolving 
10mg Valacyclovir in 10 ml volumetric flask containing 1.2 pH HCl 
and volumes was adjusted with 1.2 pH buffer to the concentration of 
1000μg/ml. From this 2.5 ml solution was withdrawn and diluted to 
25 ml to get a concentration of 100μg/ml. 
Further, from 100μg/ml, aliquots of 1 ml, 2 ml, 3 ml, 4 ml and 5 ml 
were pipetted into 10 ml volumetric flasks. The volume was made 
up with 1.2 pH HCl buffer to get the final concentration of 10, 20, 30, 
40, and 50μg/ml respectively. The absorbance was measured at 255 
nm. 
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Compatibility studies [11] 
FTIR (Fourier transform infrared spectroscopy) Studies 
Infrared spectra matching approach was used for detection of any 
possible chemical interaction between the drug and the polymer. A 
physical mixture (1:1) of drug and polymer was prepared and mixed 
with the suitable quantity of potassium bromide. About 100 mg of 
this mixture was compressed to form a transparent pellet using a 
hydraulic press at 15 tons pressure. It was scanned from 4000 to 
400 cm-1 in a Perkin Elmer FTIR spectrophotometer. The IR 
spectrum of the physical mixture was compared with that of pure 
drug and polymers which were matched to detect any appearance or 
disappearance of peaks, using FTIR peak matching method. 
Formulation of mucoadhesive tablets [12,13] 
The composition of bioadhesive Valacyclovir tablets is shown in a 
Table. 5. All ingredients were powdered and made into a wet mass 
by adding binder (PVP dissolved in Polyvinyl Alcohol) and mixed for 
10 minutes to obtain a uniform mixture. Wet mass was passed 
through sieve #60 and granules obtained are dried in an oven at 
40o 
The volume was made up to 100 ml with 1.2 pH HCl buffer and 
filtered. From the above solution, 25 ml aliquot was pipette into a 
100 ml volumetric flask and the volume was made with 1.2 pH HCl 
buffer. From this, 1 ml and 2 ml were pipetted into a 25 ml 
volumetric flask with 1.2 pH HCl buffer respectively. The absorbance 
was measured at 255 nm. This procedure was repeated thrice and 
the mean value obtained. 
C for 30 min. Magnesium stearate and talc were added to dried 
granules. Each tablet weighing 150mg was prepared by compression 
method using 8 mm flat punches in Rimek Mini Press Tablet 
compression machine.  
The present study was carried out to develop gastro retentive 
mucoadhesive tablets of Valacyclovir in order to enhance absorption 
and bioavailability by increasing gastric retention time of the dosage 
form. In this case, ten formulations of mucoadhesive tablets were 
prepared using polymers such as Carbopol 974P, HPMC K4M, MCC, 
PVP and Lactose in different concentrations and compared with 
conventional tablets. The detailed composition of each formulation 
is given in the Table. 1. 
Post compression parameters 
Post compression parameters such as appearance, thickness, 
hardness, friability, drug content uniformity, weight variation and 
swelling index were performed for the prepared tablets. 
Drug content uniformity [14] 
Twenty tablets were weighed and powdered. A quantity equivalent 
to 150mg of Valacyclovir was weighed accurately and taken in a 100 
ml volumetric flask. 50 ml of 1.2 pH HCl buffer was added and 
sonicated for 5 min.  
Swelling index [15,16] 
The tablets were coated on the lower side with ethyl cellulose (to 
avoid sticking to the dish), then weighed (w1) and placed separately 
in petri dishes containing 20 ml of pH 1.2 HCl buffer. The petri 
dishes were stored at room temperature. After 2, 4, 6 and 24 h, the 
tablets were removed and the excess liquid on their surface was 
carefully wiped using filter paper. The swollen tablets were re 
weighed (w2) and the swelling index was calculated by using the 
formula:  




In vitro dissolution studies [14] 
The tablets were so fixed to the paddle as to release the drug from 
the exposed side only In vitro dissolution studies were carried out in 
USP XXIV type II apparatus (Electrolab, Mumbai). The dissolution 
media was 900 ml 1.2 pH HCl at 370 C ± 0.50
Release kinetics of the prepared mucoadhesive tablets was 
evaluated using models such as zero order kinetics (cumulative 
percentage of drug release versus time), First order kinetics (log 
cumulative percentage of drug remaining to release versus time) 
and Higuchi (fraction of drug release, log Mt/Mi versus log time). 
The most suitable model for the drug release was predicted on the 
basis of regression coefficient i. e., nearer the value of regression 
coefficient towards 1, greater the suitability of best fitted release 
mechanism. 
 
Table 1: Formulation Design. 
C with stirring speed of 
50rpm for 24 h. The sample of 5 ml was withdrawn at 
predetermined time intervals of 0, 1, 2, 4, 6, 8, 12 and 24 h. An 
equivalent amount of fresh media was replaced. The withdrawn 
samples were filtered and analyzed by Ultra violet (UV) 
spectrophotometer (Shimadzu, UV 1700) at 255 nm using 1.2 pH HCl 
buffer as a blank. The drug content was calculated using the equation 
generated from standard calibration curve. Drug release in cumulative % 
from different formulations versus time was compared.  
Release kinetics [17] 
S. No. Ingredients B1 (mg) B2 (mg) B3 (mg) B4 (mg) B5 (mg) C1 (mg) C2 (mg) C3 (mg) 
1 Valacyclovir 35 35 35 35 35 35 35 35 
2 HPMC K4M 37.5 22.5 15 7.5 15 - - - 
3 Carbopol 974P 7.5 15 22.5 37.5 22.5 - - - 
4 Lactose - - - - 70 - - - 
5 MCC 62.5 70 70 62.5 - 106.5 103 99.5 
6 PVP 3 3 3 3 3 3.75 3 11.25 
7 Magnesium Stearate 3 3 3 3 3 3 3 3 
8 Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
B=Batch, C=Conventional tablet 
 
Ex vivo residence time [17] 
The ex vivo residence time was determined using a locally modified 
USP disintegration apparatus. The disintegration medium was 
composed of 800 ml pH 1.2 hydrochloric acid buffer maintained at 
370 C ± 0.50 Optimized batch formulation B3, along with the conventional tablet 
were subjected to in vivo evaluation in rabbits. All the animal 
investigations were performed as per the requisite protocol 
approved by the Institutional Animal Ethic Committee of JSS College 
of Pharmacy, Ooty, India. (Approval/Letter no. JSSCP/IAEC/M. 
PHARM/PH. CEUTICS/ 07/ 2013-14, dated 30/08/2013). A single-
dose parallel design study was carried out using unisex New Zealand 
white rabbits weighing between 2.35–2.70 kg.  
 C. A segment of goat stomach mucosa was glued to the 
surface of a glass slab, vertically attached to the apparatus. The 
mucoadhesive tablet was hydrated from one surface using 15 μl of 
1.2 pH HCl buffer, after which the hydrated surface was brought into 
contact with the mucosal membrane. The glass slab was vertically 
fixed to the apparatus and allowed to move up and down so that the 
tablet was completely immersed in the buffer solution at the lowest 
point and was out at the highest point. The time necessary for 
complete erosion or detachment of the tablet from the mucosal 
surface was recorded.  
In vivo pharmacokinetic studies in rabbit model [18] 
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The rabbits were divided into three groups containing six animals 
each. Group I animals pertained to normal control (saline solution), 
group II animals with positive control and group III with In-house 
formulation (B3). The rabbits were fasted for 12 h before drug 
administration. After drug administration rabbits were kept in their 
cages, and free access to food and water was allowed after 6 h. Serial 
blood samples (1 ml) were withdrawn from the marginal ear vein of 
the rabbit at 1, 2, 4, 8, 12, and 24 h post-administration and placed in 
the heparinized tubes. Plasma was harvested by centrifugation 
(3000 rpm, 5 min), and stored at -20°C until analysis. The content of 
Valacyclovir in plasma samples was analyzed by reversed-phase 
high-performance liquid chromatography (RP-HPLC). 
Bioanalytical Method Development and Analysis [19,20] 
The chromatographic variables for the estimation of Valacyclovir in 
blood plasma include pH, solvent strength, solvent ratio, flow rate, 
addition of peak modifiers in mobile phase, nature of the stationary 
phase, detection wavelength and Internal Standard (IS), which were 
studied and optimized for the separation and retention of the drug. 
The drug was extracted from blood plasma by protein precipitation 
technique.  
Chromatographic Conditions 
The stationary phase used in RP-HPLC was Hibar C18 (250 X 4.6 mm, 
i. d, 5 µm). The mobile phase used was acetonitrile: Phosphate buffer 
(pH 3.8) in a ratio 05:95. The flow was maintained to be 1.0 ml/min 
and the sample volume used was 20 μl. Rheodyne injector of 7725i 
was used. Acyclovir was used as IS and its run time was 6.9 min and 
drug run time was 13.1 min. Gradient pump with PDA detector with 
isocratic elution mode was used. Buffer strength was 25 mM and 
data station was LC-20AD. 
Preparation of standard and sample Valacyclovir solutions  
Standard stock solution of Valacyclovir 
Valacyclovir (10 mg) working standard was accurately weighed, 
transferred into a 10 ml volumetric flask, dissolved in Millipore 
water and made up to the volume with the same solvent to produce 
a 1mg/ml concentration of Valacyclovir. The stock solution was 
stored in a refrigerator at –20oC ± 2o C until analysis. The stock 
solution was diluted to suitable concentrations to obtain calibration 
curve standards.  
Standard stock solution of IS  
Acyclovir (10 mg) working standard was accurately weighed, 
transferred into a 10 ml volumetric flask, dissolved in Millipore 
water and made up to the volume with the same solvent to produce 
a 1mg/ml concentration of Acyclovir. The stock solution was stored 
in refrigerator at –20o C ± 2o
The bioanalytical curve of Valacyclovir was developed by spiking 0.5 
ml of Valacyclovir into a mixture of 0.5 ml of IS (Acyclovir), 0.5 ml of 
plasma and 0.5 ml of 10% perchloric acid (protein precipitating 
agent). The spiking was done in such a way that the test samples 
produced a concentration of 400, 200, 100, 50, 20, and 10 µg/ml. 
The concentration of IS was maintained at 100 μg/ml. These 
solutions were labeled and stored at –20 ± 2°C until analysis. 
C until analysis.  Calibration standards 
curve was prepared for the concentration from 10-400 µg.  
Preparation of calibration curve standards 
Preparation of plasma samples  
Plasma samples (0.5 ml) obtained from study subjects were 
transferred into 2.0 ml eppendorf tubes to which, 0.5 ml of IS and 0.5 
ml of 10% perchloric acid was added. The resulting solution was 
vortexed for 10 min. The solution was centrifuged and clear 
supernatant liquid is separated and analyzed. 
Method of analysis  
The bioanalytical calibration curve samples and plasma samples 
were injected into RP-HPLC with above chromatographic conditions 
and the chromatograms were recorded. The quantification of the 
chromatogram was performed using peak area. 
RESULTS AND DISCUSSION 
Calibration curve of Valacyclovir 
Calibration curve of the drug was developed using 1.2 pH HCl buffer 
to determine the linearity between concentration of drug in solution 
and its absorbance. It was concluded that the perfect linearity 
between the concentration and absorbance was observed when the 
concentration range was 2µg/ml to 10µg/ml. The ‘‘Slope (K)’’ and 
‘‘Intercept (C)’’ values were found to be 0.0607 and 0.012 
respectively, while linearity r2 
 
value was found to be 0.997. 
FTIR Studies 
The FTIR spectra (Figure. 1 and Table. 2) of the drug with polymer 
and excipients (HPMC K4M, MCC, lactose and Carbopol 974P) 
depicted no major shifting, loss or appearance of functional peaks 
between the spectra of drug, excipients and physical mixture of drug 
and excipients. This confirms that the drug and excipients were 
compatible with each other without any chemical interaction.  
 
Fig. 1: FTIR Spectra of Physical mixture (Valacyclovir, lactose, 
HPMC, MCC and Carbopol)
 
Table 2: Compatibility studies of drug with excipients by infrared spectroscopy 
S. No. Drug/Polymer Functional group Report 




2. Lactose -OH (3532.24,3325.56,2931,84,2900.32) - 
3. HPMC -OH (3456.33,2920.14) 
-C-O (1053.54) 
- 
4 Carbopol R-COOH(2924.22) 
-C=O(1698.75) 
- 
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Angle of Repose(θ) Bulk density Tapped density Carr’s index Hausner’s ratio 
B1 19±0.2 0.42±0.1 0.50±0.8 12±0.9 1.19±0.8 
B2 20±0.4 0.40±0.5 0.45±0.1 12±0.5 1.125±0.1 
B3 18±0.3 0.39±0.7 0.42±0.6 14±0.6 1.076±0.3 
B4 17±0.2 0.41±0.2 0.48±0.3 15±0.1 1.17±0.7 
B5 18±0.1 0.40±0.1 0.46±0.7 16±0.3 1.15±0.2 
C1 21±0.3 0.38±0.2 0.42±0.7 15±0.3 1.19±0.2 
C2 24±0.3 0.40±0.2 0.40±0.7 12±0.3 1.16±0.2 
C3 28±0.3 0.39±0.2 0.49±0.7 13±0.3 1.22±0.2 
*Mean±S. D (n=3) 
 
Precompression evaluation parameters 
The powder characteristics (Table. 3) of the prepared formulations 
B1, B2, B3, B4 and B5 and conventional tablets C1, C2 and C3 defined 
the angle of repose to be between 20-30 range, indicating good flow 
property, while Carr’s index was found to be between 12-16 
indicating good compressibility and Hausner’s ratio was < 1.25, 
indicating ease of powder. 
Post compression evaluation parameters 
Organoleptic properties of prepared formulation were determined 
with naked eye and all the formulations were found to be white in 
color and odorless.  
Weight variations were determined using 20 tablets in each batch. 
All the batches were found to be within the range and a single tablet 
deviated more than 10 percent from the average weight (Table. 4). 
Hardness test of the prepared mucoadhesive and conventional 
tablets was performed with Monsanto hardness tester which found 
that the tablets were in range of 6.01-6.91 kg/cm2 
Drug content was estimated in formulations B1, B2, B3, B4, B5 and 
conventional tablets C1, C2 and C3 using 1.2 pH HCl, found to be 
95.32%, 97.56%, 99.56%, 95.78% and 97.98%, while that for 
conventional tablets was 95.21%, 98.77% and 97.98% respectively 
(Table. 4). Thickness, hardness and friability was performed and 
found to be in range (Table. 4). 
 
Table 4: Post compression evaluation parameters 
(Table.4).  
Formulation code Evaluation parameters 
Thickness ± S. D. (mm) 
(n = 5) 
Hardness ± S. D. (kg/cm2 Friability 
(%) 
) 
(n = 5) 
Average weight 
variation (%) (n=10) 
Drug content 
(%) 
B1 1.52 ± 0.043 6.58 ± 0.381 0.024 0.505 ± 0.01 95.32 
B2 1.67 ± 0.055 6.25 ± 0.433 0.279 0.503 ± 0.01 97.56 
B3 1.65 ± 0.085 6.5 ± 0.5 0.184 0.498 ± 0.01 99.56 
B4 1.69 ± 0.067 6.91 ± 0.144 0.041 0.502 ± 0.13 95.78 
B5 1.52 ± 0.054 6.16 ± 0.288 0.008 0.503 ± 0.17 97.98 
C1 1.50 ± 0.043 6.09 ± 0.268 0.032 0.565 ± 0.11 95.21 
C2 1.68 ± 0.014 6.09 ± 0.168 0.254 0.572 ± 0.08 98.77 
C3 1.50 ± 0.054 6.01 ± 0.288 0.238 0.489 ± 0.03 97.98 
*Mean±S. D 
 
Table 5: Swelling index values of Mucoadhesive Valacyclovir Tablets 
Formulation code Time in hours 
2h swelling (%) 4h swelling (%) 6h swelling (%) 8h swelling (%) 24 h swelling (%) 
B1 51.11 83.30 120.43 140.49 160.55 
B2 48.6 59.44 110.13 177.77 Erosion 
B3 59.7 69.72 80.08 120.80 195.83 
B4 11.11 73.61 121.80 184.72 148.25 
B5 6.38 56.52 98.47 124.60 Erosion 
 
Swelling Index 
Adequate swelling is a crucial attribute for consistent and extended 
drug release. The swelling properties for formulations B1 to B5 were 
evaluated. The formulations B1, B3, and B4 demonstrated maximum 
swelling index which was calculated with relation to time (Table. 5). 
The swelling index was found to be enhanced as the weight gained 
by tablets increased in direct proportion with rate of degradation of 
polymers in the swelling medium. All formulation batches evidenced 
swelling between 2 h to 24 h. 
In vitro drug release of prepared formulations 
In vitro drug release studies were carried out for the prepared 
gastro retentive mucoadhesive tablets from batches (B1 to B5) and 
conventional tablets (C1 to C3) and it was found that batch B3 
showed good release profile. Increase in concentration of HPMC 
shows the retard in release of drug from the polymer and B3 batch 
having moderate amount of HPMC showed good release profile up to 
95.77% for period of 24h when compared with convention tablet 
release profile (Figure. 2). The B3 formulation was further subjected 
for in vitro release kinetic studies. 
 
 
Fig. 2: In vitro release profile of formulations (B1-B5, C1-C3) 
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In vitro data analysis release kinetics for optimized formulation 
Release data modeling studies were performed using the Zero order. 
First order. Higuchi and Korsmeyer-Peppas model and data is shown 
in Figure.3, 4, 5 and 6.  
 
 
Fig. 3: Zero order model of B3 formulation 
 
 
Fig. 4: First-Order release model of B3 formulation 
 
 
Fig. 5: Higuchi model of B3 formulation 
 
 
Fig. 6: Korsmeyer-Peppas Plot of B3 formulation 
The correlation coefficients (r2) of B3 formulation of Valacyclovir 
tablet was high enough to evaluate the drug dissolution behavior 
(r2
 
Fig.7: In vitro residence time of B3 formulation 
 
Pharmacokinetic Studies 
Optimization of chromatographic conditions  
Blank plasma, standard and sample solutions were injected and the 
chromatograms were recorded. The optimized conditions and the 
mobile phase used for estimation provided a well defined separation 
between the drug, internal standard and endogenous components. 
The blank plasma samples showed no interference at retention time 
of the drug and internal standard. Estimation of plasma samples 
from the rabbit was carried out using the optimized 
chromatographic conditions. The standard and sample solutions 
were injected and chromatograms were recorded. The calibration 
curve was constructed routinely for spiked plasma containing 
Valacyclovir and internal standard. Figure.8 represents the 
calibration curve data. The zero hour (pre-dose) samples of all 
subjects showed no interference at the retention time of both 
Valacyclovir and IS. The response factor of the standard and sample 
solutions was calculated. The concentration of Valacyclovir present 
in plasma samples were calculated and given in Table. 6. 
 
=0.95-0.99) which indicates that, the prepared gastro retentive 
mucoadhesive tablet formulations followed first order kinetics and 
the mechanism of release is Quasi-Fickian. 
In vitro residence time of Valacyclovir optimized formulation (B3) 
The ideal batch depending upon the in vitro release profile selected 
was B3 and subjected for in vitro residence time study (Figure. 7), 
and it was found that the batch B3 formulation resided for 24h with 
continuous time interval swelling and erosion. 
 
 
Fig. 8: Bioanalytical calibration curve 
 
Pharmacokinetics data 
The pharmacokinetic data of C3 and B3 formulations were shown in 
Table. 6 and Figure. 9. The mean plasma concentration of C3 and B3 
was found to be 545.19 and 567.26 respectively.  
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On oral administration of C3 and B3 in fasting stage, exhibited blood 
levels in all the rabbits from 1h onwards. The B3 formulation has 
shown a control release over a period of 24h with a Tmax 
Kinetic profile 
of 8h when 
compared to that of C3 formulation. Hence it indicates that B3 
formulation has retained more time in stomach leads to controlled 
release of the formulation. The intake of food also didn’t interfere 
with the release profile of B3 formulation.  
 
Table 6: Pharmacokinetic profile 
Conventional Tablet (C2) Ideal batch (B3) 
Cmax 545.19  (µg/ml) 567.26 
Tmax 2  (h) 8 
t1/2 2.4 (h) 5.99 
Ke (h-1 0.29 ) 0.12 
AUC0-t 2006.155 (µg/ml) 6088.925 
AUC0-α 2314.53 (µg/ml) 6745.1 
 
 
Fig. 9: Blood plasma curve 
 
CONCLUSION 
A stable gastro retentive mucoadhesive dosage form of Valacyclovir 
was developed for controlled release. Peak plasma concentration 
(Cmax567.26µg/ml) achieved was greater than that of conventional 
dosage form. Tmax was found to be increased than conventional 
dosage form. The t1/2 was found to have increased to 5.99 h, as the 
release is retarded by polymer and decreased elimination Ke up to 
0.12h -1 . AUC0-t and AUC0-α 
1. Brien JJ, Richards DM. O' Campoli Acyclovir. An updated review 
of its antiviral activity pharmacokinetic properties and 
therapeutic efficacy. Drugs 1989;37:233-309. 
was found to be increased than that of 
conventional tablet i. e., (6088.925µg/ml and 6745.1µg/ml 
respectively). Mucoadhesive drug delivery or gastroretentive drug 
delivery system can be used as an alternative to conventional dosage 
forms for the class of drugs, which undergoes intestinal or enzymatic 
degradation. From this study it can be concluded that a successful 
mucoadhesive control drug delivery system for Valacyclovir has 
been developed by using mucoadhesive polymers such as Carbopol 
974P and HPMC. 
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